4d agoThe FlyBEARISH 42Analyst
Archived explainer. For the current picture see today's NVS page.
Why Is NOVARTIS AG ADR (NVS) Stock Down Today?
By the Top Tier Newswire AI Desk · September 9, 2026 at 12:10 AM ET · reviewed against 47 wire stories
NOVARTIS AG ADR (NVS) is down -13.93% in the latest session. Our newswire has captured 47 stories on NVS across 22 sources in the last 36 hours, with AI sentiment reading bearish (avg 37/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why NVS stock is down today
Novartis AG ADR (NVS) fell 13.93% to $137.70 in a session marked by a significant blow to its drug development pipeline. The stock’s worst day in over two decades came after the company announced the failure of its experimental cholesterol drug del-desiran in a late-stage trial. This setback has raised concerns about the broader Lp(a) drug class, affecting not only Novartis but also competitors like Amgen and Eli Lilly.
What Happened
The company disclosed on Tuesday that del-desiran did not meet its primary endpoint in a key cardiovascular trial. This is the second major trial failure in a week for Novartis, further deepening investor concerns. The failure of the drug has cast a shadow over the company’s prospects in the cholesterol treatment market and triggered a broad sell-off in related biotech stocks. Mizuho analysts noted that the selloff in Sarepta shares following the Novartis setback appears overdone, but the market has not yet found a floor. Deutsche Bank downgraded the stock to Hold from Buy, while RBC Capital initiated coverage with a Sector Perform rating. The stock’s sharp decline has also led to a broader market reaction, with Amgen falling 10% as investors reevaluated the entire Lp(a) drug class.
What The Data Shows
The stock has declined 11.1% over the past eight sessions, moving from $155.21 to $137.98. On September 8, the stock printed two fresh 52-week highs and 21 fresh 52-week lows, highlighting the volatility. The current price of $137.70 is within the 52-week range of $121.57 to $170.46. The stock’s beta of 0.49 suggests it is less volatile than the market, yet the recent drop has been severe. Retail traders on social media platforms have noted the stock’s underperformance, with some calling it oversold. Congressional trades show recent activity, with Senator Alan Armstrong buying shares in the $1,001-$50,000 range on March 30 and March 31.
What To Watch
The stock is currently without an upcoming earnings report, so coverage breadth and analyst reactions to the trial failure will be key to watch in the coming days.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NVS by the numbers
Last: $137.70Session: -13.93%7 sessions: -10.60%Coverage: 47 stories / 22 sourcesAI sentiment: 37/100 (bearish)Mkt cap: $303.9BP/E: 24.252w: $121.57 to $170.46
The headlines behind the move
4d agoThe FlyBULLISH 56Analyst
Novartis initiated with a Sector Perform at RBC Capital
4d agoStocktwits NewsBEARISH 22Earnings
NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial.
4d agoTipRanksBEARISH 38General
Eli Lilly Stock (LLY) Falls on News of Competitor Novartis’ Cholesterol Drug Setback
Eli Lilly’s ($LLY) stock is down 2% on reports that rival Novartis’ ($NVS) new cholesterol drug failed a closely watched cardiovascular trial. The failure of the ch...
4d agoInvestors.comBEARISH 28General
How Novartis' Double-Stacked Failures Shook Biotech
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
4d agoThe FlyBULLISH 58Analyst
Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone
4d agoYahoo TopBEARISH 28General
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.
4d agoThe FlyBEARISH 32General
Novartis falls -13.8%
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on NVS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier NVS move explainers: 2026-09-09 · 2026-09-08 · 2026-09-02 · 2026-09-01